Late target lesion revascularization after implantation of sirolimus‐eluting stent

Objectives: We evaluated the incidence, clinical presentation, and angiographic in‐stent restenosis (ISR) pattern of late target lesion revascularization (TLR) after sirolimus‐eluting stent (SES) implantation. Background: Late TLR is an unusual finding beyond 6–9 months after bare‐metal stent implantation. However, late TLR after SES implantation has not been sufficiently evaluated. Methods: The study population consisted of 804 patients with 1,020 native lesions that were patent at 6‐month follow‐up angiogram after SES implantation. Results: Late TLR was performed in 18 patients with 18 lesions (1.8%) at 24.1 ± 2.6 months (range; 18–30 months) after SES implantation. Clinical presentation of late TLR patients was silent ischemia in eight patients and recurrent angina in 10 patients, but none had an acute coronary syndrome. Angiographic ISR pattern of late TLR lesions were focal ISR in 12 lesions (67%) and diffuse ISR in six lesions (33%). Serial quantitative coronary angiographic analysis of these lesions showed a minimal lumen diameter of 2.6 ± 0.5 mm immediately after SES implantation, 2.4 ± 0.4 mm at 6‐month follow‐up and 0.7 ± 0.6 mm at 24‐month follow‐up (ANOVA P < 0.001). By stepwise multiple logistic regression analysis, the only independent predictor of late TLR was stent length (P < 0.001, OR = 1.040, 95% CI = 1.019–1.061). Conclusions: Late TLR was performed in 1.8% of 1,020 native lesions that were patent at 6‐month follow‐up angiogram. Clinical presentations of late TLR was either silent ischemia or recurrent angina, but not acute coronary syndrome. Two‐thirds of late TLR lesions had a focal angiographic ISR pattern. © 2007 Wiley‐Liss, Inc.

[1]  Young-Hak Kim,et al.  Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. , 2006, European heart journal.

[2]  Seung‐Jung Park,et al.  Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. , 2005, Journal of the American College of Cardiology.

[3]  A. Kastrati,et al.  Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent. , 2005, Annals of internal medicine.

[4]  Patrick W Serruys,et al.  Four-Year Angiographic and Intravascular Ultrasound Follow-Up of Patients Treated With Sirolimus-Eluting Stents , 2005, Circulation.

[5]  Patrick W Serruys,et al.  Clinical, Angiographic, and Procedural Predictors of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Complex Patients: An Evaluation From the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Study , 2004, Circulation.

[6]  Charles L. Brown,et al.  Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis , 2004, Circulation.

[7]  K. Kent,et al.  Five-Year Follow-Up After Intracoronary Gamma Radiation Therapy for In-Stent Restenosis , 2004, Circulation.

[8]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[9]  Patrick W Serruys,et al.  Coronary Restenosis After Sirolimus‐Eluting Stent Implantation: Morphological Description and Mechanistic Analysis From a Consecutive Series of Cases , 2003, Circulation.

[10]  C. Di Mario,et al.  Preliminary Observations Regarding Angiographic Pattern of Restenosis After Rapamycin-Eluting Stent Implantation , 2003, Circulation.

[11]  Patrick W. Serruys,et al.  A randomized comparison of a sirolimus eluting stent with a standard stent for coronary revascularization , 2002 .

[12]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[13]  C. Di Mario,et al.  First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic Outcome , 2002, Circulation.

[14]  Yoshio Kobayashi,et al.  Intimal hyperplasia regression from 6 to 12 months after stenting. , 2002, The American journal of cardiology.

[15]  P. Serruys,et al.  Radioactive Stents Delay but Do Not Prevent In-Stent Neointimal Hyperplasia , 2001, Circulation.

[16]  R A Schatz,et al.  Three-year clinical and angiographic follow-up after intracoronary radiation : results of a randomized clinical trial. , 2000, Circulation.

[17]  G. Stone,et al.  Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.

[18]  HaraldMudra,et al.  Serial Follow-up After Optimized Ultrasound-Guided Deployment of Palmaz-Schatz Stents , 1997 .

[19]  E. Regar,et al.  Serial follow-up after optimized ultrasound-guided deployment of Palmaz-Schatz stents. In-stent neointimal proliferation without significant reference segment response. , 1997, Circulation.

[20]  M. Leon,et al.  Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. , 1996, Circulation.

[21]  H Yokoi,et al.  Three-year follow-up after implantation of metallic coronary-artery stents. , 1996, The New England journal of medicine.